

**AMENDMENTS TO THE CLAIMS**

*Please amend the claims as follows:*

1. – 5. (Cancelled).
6. (Currently Amended) A pharmaceutical composition, comprising:
  - (a) an antagonist of ~~hLRTM4 gene~~ or hLRTM4 gene transcript, wherein the hLRTM4 gene has the sequence of SEQ ID NO: 1, wherein the antagonist is a polynucleotide ~~having~~ consisting of a contiguous fragment of 30-100 bases that hybridize to the hLRTM4 gene or the hLRTM4 gene transcript; and
  - (b) a pharmaceutically acceptable vehicle, diluent or carrier.
7. (Previously Presented) The composition of claim 6, wherein the polynucleotide is an antisense polynucleotide for the hLRTM4 gene transcript.
8. – 16. (Cancelled).
17. (Previously Presented) The composition of claim 7, wherein the antisense polynucleotide has a contiguous fragment of at least 50 bases that hybridize to the hLRTM4 gene transcript.
18. (Currently Amended) The composition of claim 7, wherein the antisense polynucleotide has a contiguous fragment of ~~at least~~ 100 bases that hybridize to the hLRTM4 gene transcript.
19. (Previously Presented) The composition of claim 6, wherein the polynucleotide is included in an expression vector.
20. - 21. (Canceled).